GSK Must Face Wellbutrin Consumer Antitrust Suit

Law360, New York (October 27, 2010, 6:07 PM EDT) -- GlaxoSmithKline PLC has lost its bid for a judge to revisit a ruling keeping in place claims brought by employee benefit plans over GSK's alleged filing of baseless patent suits to delay generic competition with Wellbutrin SR.

In a ruling Wednesday, Judge Lawrence F. Stengel denied GSK's motion for reconsideration of his March ruling refusing to toss allegations by indirect purchasers of the company's popular antidepressant.

The suit, first filed in 2004, asserts GSK forced class members to pay higher prices for Wellbutrin SR and Zyban,...
To view the full article, register now.